662,405 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 662,405 shares of the medical research company's stock, valued at approximately $49,038,000. Alyeska Investment Group L.P. owned approximately 0.11% of Edwards Lifesciences as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth $26,000. Millstone Evans Group LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences in the fourth quarter valued at about $30,000. Roble Belko & Company Inc acquired a new position in Edwards Lifesciences in the fourth quarter valued at about $46,000. Finally, Catalyst Capital Advisors LLC bought a new position in Edwards Lifesciences during the fourth quarter worth about $54,000. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research note on Wednesday, February 12th. Truist Financial cut their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their price target for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Royal Bank of Canada reissued an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Finally, Barclays lifted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $79.45.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $0.17 during mid-day trading on Tuesday, reaching $74.94. 2,378,625 shares of the company were exchanged, compared to its average volume of 5,019,167. The stock has a market capitalization of $44.05 billion, a P/E ratio of 10.75, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company's 50-day simple moving average is $71.30 and its 200-day simple moving average is $71.41. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business's revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.66 earnings per share. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 77,833 shares of company stock valued at $5,611,023 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.